Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEPCOME-MB
2023-505302-42-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of binimetinib, encorafenib and pembrolizumab in cutaneous melanoma (CM) and melanoma (2 arms), sponsored by Unicancer. Primary endpoint: Intracranial progression-free survival. Planned start Feb 2024; status: authorised.
02
Drugs
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2023-505302-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505302-42-00.